{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:55:28Z","timestamp":1791215728434,"version":"4.1.0"},"reference-count":169,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OncoImmunology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.4161\/onci.26333","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T00:26:36Z","timestamp":1383092796000},"page":"e26333","source":"Crossref","is-referenced-by-count":161,"title":["Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses"],"prefix":"10.1080","volume":"2","author":[{"given":"Brian","family":"Baldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,10,27]]},"reference":[{"key":"R1","first-page":"1","article-title":"International drug monitoring: the role of national centres","volume":"498","author":"World Health Organization","year":"1972","journal-title":"WHO Tec Rep Ser"},{"key":"R2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"R3","unstructured":"What is a serious event? Available at http:\/www.fda.gov\/safety\/medwatch\/howtoreport\/ucm053087.htm (accessed February 18, 2013)."},{"key":"R4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(00)03167-6","article-title":"Pharmacogenetics and adverse drug reactions","volume":"356","author":"Meyer","year":"2000","journal-title":"Lancet"},{"key":"R5","unstructured":"Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachmann PJ, eds. Clinical Aspects of Immunology. Oxford: Blackwells, 1975: 761-81."},{"key":"R6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1398-9995.2008.01832.x","article-title":"Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study","volume":"64","author":"Brockow","year":"2009","journal-title":"Allergy"},{"key":"R7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0091-6749(76)90181-0","article-title":"The mode of action of aspirin and similar compounds","volume":"58","author":"Vane","year":"1976","journal-title":"J Allergy Clin Immunol"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Baldo BA, Pham NH. Drug Allergy. Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships. New York: Springer, 2013.","DOI":"10.1007\/978-1-4614-7261-2"},{"key":"R9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00144273","article-title":"Hypersensitivity reactions from antineoplastic agents","volume":"6","author":"Weiss","year":"1987","journal-title":"Cancer Metastasis Rev"},{"key":"R10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.cad.0000131685.06390.b7","article-title":"Non-allergic nature of docetaxel-induced acute hypersensitivity reactions","volume":"15","author":"Ardavanis","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","article-title":"Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers","volume":"94","author":"Went","year":"2006","journal-title":"Br J Cancer"},{"key":"R12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/mabs.2.2.11221","article-title":"Catumaxomab: clinical development and future directions","volume":"2","author":"Linke","year":"2010","journal-title":"MAbs"},{"key":"R13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"R14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3858\/emm.2011.43.10.063","article-title":"One target, different effects: a comparison of distinct therapeutic antibodies against the same targets","volume":"43","author":"Shim","year":"2011","journal-title":"Exp Mol Med"},{"key":"R15","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2967\/jnumed.107.043489","article-title":"Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice","volume":"48","author":"Jacene","year":"2007","journal-title":"J Nucl Med"},{"key":"R16","first-page":"128S","article-title":"Tositumomab and (131)I therapy in non-Hodgkin\u2019s lymphoma","volume":"46","author":"Wahl","year":"2005","journal-title":"J Nucl Med"},{"key":"R17","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin\u2019s lymphoma: implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"R18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"R19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4161\/mabs.1.4.8895","article-title":"Ofatumumab","volume":"1","author":"Zhang","year":"2009","journal-title":"MAbs"},{"key":"R20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-001-0247-1","article-title":"Binding to CD20 by anti-B1 antibody or F(ab\u2019)(2) is sufficient for induction of apoptosis in B-cell lines","volume":"51","author":"Cardarelli","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"R21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"R22","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.14536","article-title":"Panitumumab and cetuximab epitope mapping and in vitro activity","volume":"26","author":"Freeman","year":"2008","journal-title":"J Clin Oncol"},{"key":"R23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"R24","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/0008-5472.CAN-10-1872","article-title":"Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers","volume":"71","author":"Ghosh","year":"2011","journal-title":"Cancer Res"},{"key":"R25","first-page":"350","article-title":"Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer","volume":"12","author":"Niculescu-Duvaz","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"R26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00259-005-1902-0","article-title":"[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells","volume":"32","author":"Persson","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"R28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat Biotechnol"},{"key":"R29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2006.08.002","article-title":"Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer","volume":"33","author":"Ellis","year":"2006","journal-title":"Semin Oncol"},{"key":"R30","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/sj.onc.1210380","article-title":"Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Alinari","year":"2007","journal-title":"Oncogene"},{"key":"R31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"R32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"R33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/OTT.S4833","article-title":"CTLA-4 blockade: therapeutic potential in cancer treatments","volume":"3","author":"Tarhini","year":"2010","journal-title":"Onco Targets Ther"},{"key":"R34","unstructured":"European Medicines Agency evaluation of medicines for human use. Assessment report for Removab. Proc. no. EMEA\/H\/C\/000972, 2009. Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-Public_assessment_report\/human\/000972\/WC500051808.pdf (accessed at July 1, 2013)."},{"key":"R35","unstructured":"Therapeutic Goods Administration. Australian public assessment report for catumaxomab, October 2012. Available at http:\/\/www.tga.gov.au\/pdf\/auspar\/auspar-catumaxomab-121004.pdf (accessed July 1, 2013)."},{"key":"R36","unstructured":"Zevalin\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125019s0156.pdf (accessed July 1, 2013)."},{"key":"R37","unstructured":"Bexxar\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125011s102lbl.pdf (accessed July 1, 2013)."},{"key":"R38","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"R39","unstructured":"Adcetris\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125388s0005lbl.pdf (accessed July 1, 2013)."},{"key":"R40","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"R41","unstructured":"Erbitux\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125084s168lbl.pdf (accessed July 1, 2013)."},{"key":"R42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1188\/05.CJON.332-338","article-title":"Cetuximab: adverse event profile and recommendations for toxicity management","volume":"9","author":"Thomas","year":"2005","journal-title":"Clin J Oncol Nurs"},{"key":"R43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1756-9966-28-113","article-title":"Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review","volume":"28","author":"Hoag","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"R44","unstructured":"Polito AJ. Pulmonary reactions to novel chemotherapeutic agents and biomolecules. In: Camus P, Rosenow III EC, eds. Drug-Induced and Iatrogenic Respiratory Disease. London: HodderArnold, 2010: 146-60."},{"key":"R45","unstructured":"Rituxan\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf (accessed July 1, 2013)."},{"key":"R46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ajh.21372","article-title":"Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon","volume":"84","author":"Ram","year":"2009","journal-title":"Am J Hematol"},{"key":"R47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"R48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1445-5994.2010.02384.x","article-title":"Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura","volume":"41","author":"Le Guenno","year":"2011","journal-title":"Intern Med J"},{"key":"R49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000051713","article-title":"Rituximab-induced vasculitis","volume":"203","author":"Dereure","year":"2001","journal-title":"Dermatology"},{"key":"R50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab-induced lung disease: A systematic literature review","volume":"35","author":"Liot\u00e9","year":"2010","journal-title":"Eur Respir J"},{"key":"R51","unstructured":"Campath-1H\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/103948s5070lbl.pdf (accessed July 1, 2013)."},{"key":"R52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/S\u00e9zary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"key":"R53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12254-010-0174-y","article-title":"Haemolytic anaemia triggered by antitumoural \u201cbiological agents\u201d and immunotherapies with monoclonal antibodies: short review of the literature","volume":"3","author":"Sun","year":"2010","journal-title":"memo"},{"key":"R54","unstructured":"Avastin\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125085s0238lbl.pdf (accessed July 1, 2013)."},{"key":"R55","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab","volume":"66","author":"Shord","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R56","first-page":"437","article-title":"Bevacizumab-induced bowel perforation","volume":"111","author":"Sliesoraitis","year":"2011","journal-title":"J Am Osteopath Assoc"},{"key":"R57","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdr432","article-title":"Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis","volume":"23","author":"Cortes","year":"2012","journal-title":"Ann Oncol"},{"key":"R58","unstructured":"Perjeta\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125409lbl.pdf (accessed July 1, 2013)."},{"key":"R59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/BCTT.S23560","article-title":"Role of pertuzumab in the treatment of HER2-positive breast cancer","volume":"4","author":"Hubalek","year":"2012","journal-title":"Breast Cancer: Targets and Therapy"},{"key":"R60","unstructured":"Herceptin\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5256lbl.pdf (accessed July 1, 2013)."},{"key":"R61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CBC.2008.n.034","article-title":"Severe thrombocytopenia induced by a single infusion of trastuzumab","volume":"8","author":"Parikh","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"R62","unstructured":"Kadcyla\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125427lbl.pdf (accessed July 1, 2013)."},{"key":"R63","unstructured":"Xgeva\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf (accessed July 1, 2013)."},{"key":"R64","unstructured":"Yervoy\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125377s0000lbl.pdf (accessed July 1, 2013)."},{"key":"R65","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"R66","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/857519","article-title":"Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management","author":"Tarhini","year":"2013","journal-title":"Scientifica"},{"key":"R67","unstructured":"Arzerra\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125326lbl.pdf (accessed July 1, 2013)."},{"key":"R68","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-10-0570","article-title":"U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab","volume":"16","author":"Lemery","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R69","unstructured":"Vectibix\u00ae. FDA: Full prescribing information. Adverse reactions. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125147s080lbl.pdf (accessed July 1, 2013)."},{"key":"R70","first-page":"668","article-title":"Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses","volume":"85","author":"Stephens","year":"1995","journal-title":"Immunology"},{"key":"R71","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N Engl J Med"},{"key":"R72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5858\/133.2.309","article-title":"Drug-induced thrombocytopenia","volume":"133","author":"Kenney","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"R73","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.1989.tb07672.x","article-title":"Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies","volume":"72","author":"Salama","year":"1989","journal-title":"Br J Haematol"},{"key":"R74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/asheducation-2004.1.63","article-title":"Congenital and acquired neutropenia","author":"Berliner","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R75","doi-asserted-by":"crossref","unstructured":"Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hemat Educ Program 2009; 73-9.","DOI":"10.1182\/asheducation-2009.1.73"},{"key":"R76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-7022-3-5","article-title":"Management of hypersensitivity pneumonitis","volume":"3","author":"Agache","year":"2013","journal-title":"Clin Translational Allergy"},{"key":"R77","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.all.0000235898.80052.80","article-title":"Allergic hepatitis induced by drugs","volume":"6","author":"Castell","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R78","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/toxsci\/kfq009","article-title":"Mechanisms of immune-mediated liver injury","volume":"115","author":"Adams","year":"2010","journal-title":"Toxicol Sci"},{"key":"R79","unstructured":"Apisamthanarax N, Duvic M. Dermatologic complications of cancer chemotherapy. In: Bast RC Jr, Kufe DW, Pollock RE, et al. eds. Holland-Frei Cancer Medicine, 5th edn. Hamilton, Ontario: BC Decker, 2000: 2271-8."},{"key":"R80","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management","volume":"12","author":"Lynch","year":"2007","journal-title":"Oncologist"},{"key":"R81","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula","year":"2010","journal-title":"J Support Oncol"},{"key":"R82","unstructured":"Common terminology criteria for adverse events v3.0, DTCD, NCI, NIH, DHHS. Publish date: August 9, 2006 (http:\/ctep.cancer.gov)"},{"key":"R83","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"R84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1548-5315(11)70383-7","article-title":"Overview of hypersensitivity to cancer therapies","volume":"7","author":"O'Neil","year":"2010","journal-title":"Community Oncol"},{"key":"R85","doi-asserted-by":"crossref","first-page":"x313","DOI":"10.1093\/annonc\/mds314","article-title":"Prevention and handling of acute allergic and infusion reactions in oncology","volume":"23","author":"Joerger","year":"2012","journal-title":"Ann Oncol"},{"key":"R86","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"R87","first-page":"131","article-title":"Review: Drug-induced neutropenia--pathophysiology, clinical features, and management","volume":"34","author":"Bhatt","year":"2004","journal-title":"Ann Clin Lab Sci"},{"key":"R88","unstructured":"Lee A, ed. Adverse Drug Reactions, 2nd edn. London: Pharmaceutical Press, 2006."},{"key":"R89","doi-asserted-by":"crossref","unstructured":"Uetrecht J, ed. Adverse Drug Reactions. Handbook of Experimental Pharmacology 196. Heidelberg: Springer-Verlag, 2010.","DOI":"10.1007\/978-3-642-00663-0"},{"key":"R90","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R91","first-page":"451","article-title":"Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management","volume":"5","author":"Kang","year":"2007","journal-title":"J Support Oncol"},{"key":"R92","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"R93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/RLU.0b013e31815ef825","article-title":"Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma","volume":"33","author":"Jankowitz","year":"2008","journal-title":"Clin Nucl Med"},{"key":"R94","doi-asserted-by":"crossref","unstructured":"Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. In Arch Allergy Immunol 2012; 159:321-6.","DOI":"10.1159\/000336839"},{"key":"R95","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e18520","article-title":"Rituximab hypersensitivity reactions (HSR): Predictors of recurrent and severe reactions based on severity of reaction, NHL histologic subtype, and burden of disease","volume":"30","author":"Sallman","year":"2012","journal-title":"J Clin Oncol"},{"key":"R96","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1006341717398","article-title":"Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy","volume":"18","author":"Dillman","year":"1999","journal-title":"Cancer Metastasis Rev"},{"key":"R97","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"key":"R98","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"R99","first-page":"105","article-title":"Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients","volume":"16","author":"Tonini","year":"2002","journal-title":"J Biol Regul Homeost Agents"},{"key":"R100","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1634\/theoncologist.12-3-338","article-title":"Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab","volume":"12","author":"Hayslip","year":"2007","journal-title":"Oncologist"},{"key":"R101","first-page":"80","article-title":"Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia","volume":"25","author":"Diehl","year":"1998","journal-title":"Semin Oncol"},{"key":"R102","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R103","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R104","first-page":"ECR23","article-title":"Rituximab-induced acute thrombocytopenia: a report of two cases","volume":"90","author":"Otrock","year":"2005","journal-title":"Haematologica"},{"key":"R105","first-page":"1870","article-title":"Drug induced thrombocytopenia","volume":"357","author":"Cathomas","year":"2007","journal-title":"N Engl J Med"},{"key":"R106","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/annonc\/mdp374","article-title":"Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease","volume":"20","author":"Jara S\u00e1nchez","year":"2009","journal-title":"Ann Oncol"},{"key":"R107","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/10245330400001942","article-title":"Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy","volume":"9","author":"Haider","year":"2004","journal-title":"Hematology"},{"key":"R108","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"key":"R109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.2005.05570.x","article-title":"Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders","volume":"130","author":"Gibbs","year":"2005","journal-title":"Br J Haematol"},{"key":"R110","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R111","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"R112","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","article-title":"Rituximab-associated neutropenia","volume":"47","author":"Dunleavy","year":"2010","journal-title":"Semin Hematol"},{"key":"R113","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N Engl J Med"},{"key":"R114","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","article-title":"Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases","volume":"26","author":"Papadaki","year":"2002","journal-title":"Leuk Res"},{"key":"R115","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","article-title":"Chronic neutropenia mediated by fas ligand","volume":"95","author":"Liu","year":"2000","journal-title":"Blood"},{"key":"R116","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-05-1532","article-title":"Rituximab-associated immune myelopathy","volume":"102","author":"Papadaki","year":"2003","journal-title":"Blood"},{"key":"R117","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.11031","article-title":"Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery","volume":"92","author":"Terrier","year":"2007","journal-title":"Haematologica"},{"key":"R118","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/1042819021000055110","article-title":"Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder","volume":"44","author":"Jourdan","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"R119","first-page":"747","article-title":"Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis","volume":"47","author":"Ramamoorthy","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ajh.21330","article-title":"Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab","volume":"84","author":"Ruch","year":"2009","journal-title":"Am J Hematol"},{"key":"R121","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.10733","article-title":"Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients","volume":"92","author":"Elimelakh","year":"2007","journal-title":"Haematologica"},{"key":"R122","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ajh.21086","article-title":"Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab","volume":"83","author":"Kako","year":"2008","journal-title":"Am J Hematol"},{"key":"R123","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1002\/cncr.22263","article-title":"Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria","volume":"107","author":"Fiegl","year":"2006","journal-title":"Cancer"},{"key":"R124","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.25379","article-title":"Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Cancer"},{"key":"R125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangi\u00e9","year":"2007","journal-title":"Lancet Oncol"},{"key":"R126","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"R127","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1445-5994.2005.00899.x","article-title":"Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis","volume":"35","author":"Anandacoomarasamy","year":"2005","journal-title":"Intern Med J"},{"key":"R128","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archderm.142.2.246","article-title":"Rituximab-induced leukocytoclastic vasculitis: a case report","volume":"142","author":"Kandula","year":"2006","journal-title":"Arch Dermatol"},{"key":"R129","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1346-8138.2009.00639.x","article-title":"Rituximab-induced vasculitis: A case report and review of the medical published work","volume":"36","author":"Kim","year":"2009","journal-title":"J Dermatol"},{"key":"R130","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)","volume":"44","author":"D\u2019Arcy","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R131","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdg488","article-title":"Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment","volume":"14","author":"Hellerstedt","year":"2003","journal-title":"Ann Oncol"},{"key":"R132","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.rhu.0000262585.18582.1e","article-title":"Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia","volume":"13","author":"Finger","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"R133","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment","volume":"26","author":"Fong","year":"2008","journal-title":"J Clin Oncol"},{"key":"R134","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","article-title":"Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade","volume":"175","author":"Maker","year":"2005","journal-title":"J Immunol"},{"key":"R135","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"R136","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-7022-3-5","article-title":"Management of hypersensitivity pneumonitis","volume":"3","author":"Agache","year":"2013","journal-title":"Clin Translational Allergy"},{"key":"R137","doi-asserted-by":"crossref","first-page":"680431","DOI":"10.1155\/2012\/680431","article-title":"Rituximab-induced bronchiolitis obliterans organizing pneumonia","volume":"2012","author":"Ergin","year":"2012","journal-title":"Case Rep Med"},{"key":"R138","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1056\/NEJM200306263482619","article-title":"Interstitial pneumonitis related to rituximab therapy","volume":"348","author":"Burton","year":"2003","journal-title":"N Engl J Med"},{"key":"R139","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ajh.20910","article-title":"Rituximab-induced interstitial lung disease","volume":"82","author":"Wagner","year":"2007","journal-title":"Am J Hematol"},{"key":"R140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/rheumatology\/kep015","article-title":"A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus","volume":"48","author":"Kishi","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R141","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: a systematic review","volume":"51","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R142","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","article-title":"Fatal pulmonary fibrosis after rituximab administration","volume":"24","author":"Chaumais","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R143","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00467-009-1408-2","article-title":"Severe respiratory adverse events associated with rituximab infusion","volume":"25","author":"Kamei","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R144","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/j.1445-5994.2011.02701.x","article-title":"Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura","volume":"42","author":"Child","year":"2012","journal-title":"Intern Med J"},{"key":"R145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/RHU.0b013e31823ee5bf","article-title":"Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"18","author":"Arulkumaran","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"R146","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1532\/IJH97.NA0506","article-title":"Acute respiratory distress syndrome after rituximab infusion","volume":"82","author":"Montero","year":"2005","journal-title":"Int J Hematol"},{"key":"R147","first-page":"2691","article-title":"Interstitial pneumonitis related to rituximab therapy","volume":"348","author":"Benyunes","year":"2003","journal-title":"N Engl J Med"},{"key":"R148","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/01.TP.0000074700.30536.76","article-title":"Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis","volume":"76","author":"Alho","year":"2003","journal-title":"Transplantation"},{"key":"R149","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/10428190410001697359","article-title":"Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma","volume":"45","author":"Alexandrescu","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R150","unstructured":"Gon\u04abalo M, Bruynzeel DP. Mechanisms in cutaneous drug hypersensitivity reactions. In: Zhai H, Wilhelm K-P, Maibach HI, eds. Marzulli and Maibach\u2019s Dermatotoxicology, 7th edn. Boca Raton Florida: CRC Press, 2008: 259-68."},{"key":"R151","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdf350","article-title":"Stevens-Johnson syndrome after treatment with rituximab","volume":"13","author":"Lowndes","year":"2002","journal-title":"Ann Oncol"},{"key":"R152","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D34NS1K655","article-title":"A review of rituximab in cutaneous medicine","volume":"12","author":"Scheinfeld","year":"2006","journal-title":"Dermatol Online J"},{"key":"R153","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"R154","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr Oncol"},{"key":"R155","first-page":"4","article-title":"Clinical presentation and pathophysiology of EGFRI dermatologic toxicities","volume":"21","author":"Mitchell","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"R156","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.seminoncol.2003.08.007","article-title":"Trastuzumab and cardiac dysfunction: update on preclinical studies","volume":"30","author":"Klein","year":"2003","journal-title":"Semin Oncol"},{"key":"R157","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"R158","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","article-title":"Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy","volume":"44","author":"Grazette","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R159","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"R160","unstructured":"Brooks B. Progressive multifocal leukoencephalopathy. In: Gilman S ed. Neurobiology of Disease. London: Elsevier Academic Press, 2007: 185-96."},{"key":"R161","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"R162","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","article-title":"Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003","volume":"113","author":"Johansson","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"R163","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2010-03-276691","article-title":"Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods","volume":"116","author":"Reese","year":"2010","journal-title":"Blood"},{"key":"R164","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2012.04664.x","article-title":"Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia","volume":"10","author":"Arnold","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0887-7963(93)70146-7","article-title":"Drug-induced immune neutropenia","volume":"7","author":"Stroncek","year":"1993","journal-title":"Transfus Med Rev"},{"key":"R166","first-page":"12","article-title":"Drug-induced vasculitis: a clinical and pathological review","volume":"70","author":"Radi\u0107","year":"2012","journal-title":"Neth J Med"},{"key":"R167","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno","year":"2012","journal-title":"Respir Res"},{"key":"R168","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2214\/ajr.175.4.1751019","article-title":"Drug-induced lung disease: high-resolution CT findings","volume":"175","author":"Ellis","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"R169","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/ers.11.19","article-title":"Bronchiolitis obliterans organizing pneumonia, 25 years: a variety of causes, but what are the treatment options?","volume":"5","author":"Epler","year":"2011","journal-title":"Expert Rev Respir Med"}],"container-title":["OncoImmunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/onci.26333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T22:53:05Z","timestamp":1646952785000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/onci.26333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":169,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,27]]},"published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.4161\/onci.26333"],"URL":"https:\/\/doi.org\/10.4161\/onci.26333","relation":{},"ISSN":["2162-402X"],"issn-type":[{"value":"2162-402X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}